News

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 6, 2026.

Mitzi Joi Williams, MD, and Marcus Gates, MD, discuss recognizing cervical nerve root and spinal cord compression, navigating treatment options, and determining when surgery may be appropriate.

Episode 5 of Gray Areas features a conversation with Tobia Zanotto, PhD, examining whether frailty in multiple sclerosis is a preventable condition, what the current evidence on rehabilitation interventions shows, and where research needs to go next.

Amanda L. Piquet, MD, reviews 1-year KYSA-8 findings, highlighting sustained clinical improvements and safety outcomes with miv-cel in patients with stiff person syndrome.

Servier reported that sevasemten did not meet its primary or secondary end points in the pivotal GRAND CANYON trial for Becker muscular dystrophy.

QurAlis reported interim ANQUR trial results showing target engagement, a biomarker signal, and a trend toward slower functional decline with QRL-201 in ALS.

An epileptologist at Cleveland Clinic discussed findings from a recently published study of lifestyle interventions in epilepsy and why these approaches should complement rather than replace antiseizure medications.

The 500-participant study will assess whether pridopidine, an investigational sigma-1 receptor agonist, can slow functional decline and improve survival in patients with early, rapidly progressing amyotrophic lateral sclerosis.

The staff neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic discussed open-label extension data from the phase 2 CALLIPER trial of vidofludimus calcium in progressive multiple sclerosis. [WATCH TIME: 6 minutes]

IJMSC editor-in-chief, François Bethoux, MD, and colleagues cover idea generation, poster conversion, literature reviews, and peer review in a 4-part webinar series for MS clinicians.

uniQure presented final safety and biomarker results from the discontinued EPISOD1 trial of AMT-162, an investigational gene therapy for SOD1-associated ALS.

Richard Nowak, MD, director of the Yale Myasthenia Gravis Clinic and global principal investigator of the MINT trial, discusses open-label extension findings for inebilizumab, a CD19-directed B cell depleting therapy, in generalized myasthenia gravis.

The executive medical director at AbbVie discussed the FDA approval of tavapadon, the first D1/D5 dopamine agonist for Parkinson disease, including the supporting TEMPO trial data and safety considerations.

Alnylam Pharmaceuticals reported initial Phase 1b findings showing brezosiran reduced cerebrospinal fluid mutant huntingtin levels by a mean of 60% to 64% at 3 months, with plans for a pivotal study in 2027.

The president and founder of the Stuttering Treatment and Research Society (STARS) discussed highlights from the society's 2026 conference, its new interdisciplinary consensus guidelines, and the next steps for stuttering care. [WATCH TIME: 5 minutes]

AL-S Pharma outlined the design of AP101-03, a planned phase 3 trial of AP-101 in sporadic and SOD1-associated ALS, at the 2026 NEALS Annual Meeting.

Sabirnetug failed to meet its primary endpoint in Acumen Pharmaceuticals' phase 2 ALTITUDE-AD trial for early Alzheimer disease, prompting the company to end development.

The director of the Pediatric Neuromuscular Program at UCSF Benioff Children’s Hospital San Francisco discussed 2-year findings from the phase 2/3 VIBRANCE-MG study of nipocalimab in adolescents with generalized MG. [WATCH TIME: 6 minutes]

Pediatric epilepsy care goes beyond seizures, addressing mental health, learning needs, coordinated referrals, equitable access, and smoother transition to adult services.

The FDA accepted uniQure's biologics license application for ifezuntirgene inilparvovec and granted it Priority Review, setting a target action date of May 1, 2027.

Jeffrey Cohen, MD, professor of neurology and staff physician at the Cleveland Clinic Mellen Center for Multiple Sclerosis, discusses interim BREAKFREE-2 findings for zola-cel, a CD19-directed CAR T cell therapy, in relapsing and progressive MS.

Ali Habib, MD, a neuromuscular specialist at UCI Health, breaks down the phase 3 NIMBLE trial's patient population, four treatment arms, and primary efficacy endpoint while explaining the rationale for studying complement inhibition in gMG.

Ali Habib, MD, neuromuscular specialist at UCI Health, explains the rationale behind cemdisiran's liver-directed RNA interference approach and how it differs from established C5 inhibition strategies in generalized myasthenia gravis.

Here's some of what is coming soon to NeurologyLive® this week.

Interim phase 1b/2a data showed all patients treated with high- or low-dose BB-301 for oculopharyngeal muscular dystrophy met formal response criteria.

Although ocular signs in LEMS are typically mild and appear late, recognizing them alongside proximal weakness and autonomic symptoms can speed diagnosis and earlier detection of an associated lung cancer.

Neurology News Network for the week ending October 31st, 2026. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 30, 2026.